Renal dysfunction is a common complication of plasma cell myeloma (PCM) that may be severe enough to necessitate hemodialysis. Although high-dose chemotherapy and hematopoietic cell transplant (HCT) appears superior to conventional chemotherapy in likelihood of achieving CR and is associated with improvement in and, at times, reversal of renal dysfunction, many patients remain dialysis-dependent presenting the challenge of renal transplantation in this population. We reviewed the published literature and summarize the outcomes on dual organ (HCT and renal allograft) transplantation in patients with PCM and dialysis-dependent renal failure. In a literature review of 14 reports, 26 of 166 dialysis-dependent patients became dialysisindependent. Our review includes a very heterogenous patient population but suggests that HCT and renal allograft may be feasible in a subset of PCM patients with dialysis-dependent renal failure. Although there is a concern for renal allograft rejection upon withdrawal of immunosuppression, data suggest that resumption of antirejection therapy leads to stable renal function. Bortezomib potentially can be used as maintenance treatment in patients who have not achieved a CR while preventing renal allograft rejection. The literature that describes dual transplants has included patients with long-term follow-up (47 years in some patients). It is possible, however, that there may be publication bias with only favorable results being reported. More research is necessary to further delineate the subset of PCM patients most likely to benefit from renal transplant. A special registry for data collection for long-term follow-up may be useful to improve future patient survival.
INTRODUCTION
Clinically significant renal impairment is a common feature in plasma cell myeloma (PCM), affecting 20-55% of patients at initial diagnosis;
1-3 2-3% of patients present with renal failure sufficiently severe to require hemodialysis. [4] [5] [6] [7] In early conventional chemotherapy trials, renal failure was found to be a predictor of poor prognosis. Presently, renal failure is considered to reflect a higher tumor burden with a lower median OS, in part reflecting that such patients may receive reduced doses of chemotherapy, have a higher treatment-related mortality or the combination. 8, 9 Although the severity of organ dysfunction lowers the chance of renal function recovery, it does not appear to have an impact on response to chemotherapy. [10] [11] [12] Autologous hematopoietic cell transplant (HCT) appears superior to chemotherapy in terms of inducing CR, EFS and variably OS; 13, 14 most clinical trials, however, exclude patients with severe kidney failure due to concerns of excessive toxicity and treatment-related mortality. On the other hand, there is emerging evidence that such affected PCM patients should be offered autologous HCT. Multiple retrospective studies demonstrate feasibility and potential efficacy even in the setting of hemodialysis. 3, 7, 15 The purpose of this article is to review the recent progress in the management of PCM patients with renal dysfunction, focusing especially on the feasibility of autologous HCT and renal transplant, including the assessment of suitability for renal allograft as a function of outcome after autologous HCT.
We conducted a comprehensive Medline search and reviewed all articles published in English from 1980 to the present. Search items included multiple myeloma, autologous hematopoietic SCT and renal failure. We also conducted a Medline search including the dual terminology of hematopoietic SCT and solid organ or renal transplant. We further scanned all the relevant studies and review articles for studies missed via Medline. We excluded overlap between cases reported separately that also were included in full-length articles.
SCOPE OF THE PROBLEM
Some trials showed that PCM patients experienced improvement in pre-transplant renal dysfunction with the use of autologous HCT. 16, 17 In fact, several manuscripts reported the finding of some patients achieving hemodialysis independence after autologous HCT. 15, 18, 19 Variables predicting recovery from hemodialysis included requiring dialysis for o6 months prior to undertaking autologous HCT, attainment of complete CR or near-CR and creatinine clearance at time of autologous HCT 410 mL/min. 18 The emergence over the past decade of novel therapies that target tumor biology and the microenvironment such as the proteasome inhibitor bortezomib, as well as the immunomodulatory agents thalidomide and lenalidomide, dramatically have improved outcomes for PCM patients who now enjoy longer remission duration. Nevertheless, a significant percentage of patients still remain hemodialysis-dependent. For those subjects who achieve a CR or near-CR, the question of renal allograft transplant naturally arises. Typically, these patients are not offered the option of renal allograft, but should they be?
PCM PATIENTS WITH RENAL FAILURE WITH OR WITHOUT DIALYSIS DEPENDENCE AT TIME OF AUTOLOGOUS HCT
Several studies now report data showing that disease-free survival for renal-impaired PCM patients is similar to those with normal renal function at the time of autologous HCT. Additionally, there are numerous case reports of reversal of renal dysfunction and attainment of dialysis independence in up to one-quarter of affected patients within 4-5 months of autologous HCT. 15, 18 Table 1 shows the data from 14 studies in which PCM patients with renal dysfunction underwent autologous HCT. Numbers of patients per study ranged from 1 to 678; high-dose melphalan was the most commonly used conditioning regimen with melphalan dose reduction employed in some studies based on increased serum creatinine or advanced patient age. A total of 1038 patients with plasma cell dycrasias and related disorders were reported; 166 of these subjects were dialysis-dependent at the time of transplant. Duration of dialysis dependence ranged from 5 to 412 months at the time of autologous HCT. Treatment-related mortality at 100 days was noted to be 5.1%. Dialysis independence was achieved in 26 out of 166 patients (18%) after autologous HCT.
COMBINED HCT AND RENAL ALLOGRAFTS
Although an emerging treatment with chemotherapy and immunomodulatory therapy can lead to reversal of renal dysfunction in a small proportion of PCM patients, a large number remain dialysis-dependent despite achieving CR or PR from the hematological disease. Although autologous HCT potentially can prolong disease-free survival, the renal allograft option generally is not offered to dialysis-dependent patients because of the limited number of solid organs available and concerns for shortened OS due to progression of PCM and the associated increased risk of complications. Further, the necessary chronic immunosuppression to prevent renal allograft rejection may be associated with increased risk of complications in a patient who already has had significant cytotoxic agent exposure and already likely experienced opportunistic infection. Although there is no evidence that immunosuppression exacerbates myeloma, it is difficult to balance simultaneous chemotherapy and immunosuppression.
Combined renal allograft transplantation with HCT from the same donor using a non-myeloablative conditioning regimen offers the potential to cure the primary hematological malignancy while allowing acceptance of the renal allograft without the necessity of chronic immunosuppression. Table 2 shows data on patients with varied hematological disorders and renal failure who subsequently underwent renal allografts for nephropathy after prior allogeneic and autologous HCT. Some patients undergoing allogeneic HCT for a primary BM disorder (AML in most cases) subsequently developed chronic renal insufficiency, progressing to dialysis dependence for a variety of reasons including chronic exposure to calcineurin inhibitors. These patients may have received a renal transplant from the same donor, 20-26 matched sibling donor 23 or living or cadaveric unrelated donor. 23 Table 2 lists a total of 42 patients from nine studies, 30 of whom received HCT from matched related donors, 3 from parents, 7 from matched unrelated donors, 1 mismatched unrelated donor and 1 autologous HCT. Time from HCT to renal transplantation (for dialysis-dependent renal failure) ranged from 8 months to 19 years; the most common etiology for renal failure was HCTassociated nephropathy. The kidney allograft was obtained from the same donor source as the hematopoietic cell donor in 21 patients, procured from unrelated living or cadaveric donors in 18 patients and obtained from a matched sibling in 1 patient. A total of 44 renal transplants were performed in 42 patients. Follow-up ranged from 3 months to 8.9 years; only one patient was lost to follow-up. In all, 15 of the 23 patients who received BM and solid organ from the same donor were able to be taken off immunosuppression; most received short-term immunosuppression with corticosteroids with or without CYA. In these patients, renal function remained stable and without renal graft rejection. On the other hand, patients who received the different types of grafts from disparate renal and BM donors continued to require chronic immunosuppression with prednisone, tacrolimus, mycophenolate, CYA or varying combinations. Overall, there were six deaths at last follow-up, two from cancer, 23, 27 two from infectious etiologies, 28 one from interstitial lung disease 28 and one from ischemic cardiomyopathy. 27 Although the shorter duration of immunosuppression decreased the incidence of serious and life-threatening infections in the patients receiving combined HCT and renal allografts, the data indicate that OS still is dependent upon long-term complications of HCT due to myeloablative and toxic conditioning regimens. These data suggest that although combined allogeneic HCT and renal transplant in PCM patients may be a feasible and viable option in dialysis-dependent patients, it remains to be seen whether such an approach can be achieved with the aid of less toxic conditioning regimens. Table 3 shows plasma cell dyscrasia patients who received autologous HCT either before or after renal allograft. These 10 patients ranged in age from 48 to 65 years, 6 had a diagnosis of primary amyloidosis, 2 had PCM and 2 with light-chain deposition disease. Leung et al. 29 reported five patients with a primary diagnosis of systemic amyloidosis with renal failure who received renal allografts prior to HCT. Two other patients had prior renal transplantation followed by PCM 12 years later. 30 Follow-up ranged from 8 months to 15 years from time of first transplant (renal or HCT). Immunosuppression was continued in all patients with tacrolimus, prednisone, mycophenolate, sirolimus and azathioprine in varying combinations. Only one patient had mild chronic nephropathy, 29 whereas the other nine patients maintained normal (N ¼ 4) or stable (N ¼ 5) renal function.
AUTOLOGOUS HCT AND RENAL TRANSPLANTATION IN PATIENTS WITH DIALYSIS-DEPENDANT RENAL FAILURE

REDUCED-INTENSITY CONDITIONING HCT USING HLA-HAPLOIDENTICAL DONORS
Although HCT potentially may be curative for various malignant and non-malignant hematological disorders, myeloablative conditioning is associated with significant morbidity and mortality. Use of HLA-matched sibling donors results in the best OS and progression-free survival, but less than one-third of allogeneic HCT candidates have suitable HLA-matched sibling donors. Further, the search to identify a matched unrelated donor may take considerable time and often is unsuccessful. On the other hand, a partially matched HLA-compatible, first-degree relative can be identified in most situations, that is, biological parent, child or sibling. These relatives can serve as alternate donors; the disadvantages with this approach include the high incidence of graft rejection, GVHD and opportunistic infection. 31, 32 The use of haploidentical transplants may expand the opportunities to provide renal allografts for patients who have developed dialysisdependent nephropathy.
Attempts to reduce conditioning-associated mortality without increasing graft rejection and GVHD have led to the emergence of reduced-intensity and non-myeloablative conditioning regimens in HLA-haploidentical HCT. Murine studies demonstrated that the Renal allograft in myeloma L Nayak and HM Lazarus Renal allograft in myeloma L Nayak and HM Lazarus use of high-dose CY given immediately after transplant can inhibit graft rejection and GVHD in MHC-matched and -mismatched HCT. 33 High-dose CY is not toxic to primitive hematopoietic cells as they possess high levels of aldehyde dehydrogenase (which confers drug resistance), yet can be toxic to recently activated effector lymphocytes that mediate the host-vs-graft and graft-vs-host reactions. Hence, timely administration of highdose CY is selectively toxic to proliferating Ag-specific donor T lymphocytes. 33 Luznik et al. 34 successfully demonstrated use of haploidentical BM donor transplants after non-myeloablative conditioning and post-transplant high-dose CY transplantation, for example, low rates of GVHD and graft failure. They reported on 67 hematological malignancies and on one paroxysmal nocturnal hemoglobinuria patient who received CY 50 mg/kg i.v. on day 3 (N ¼ 28) or on days 3 and 4 (N ¼ 40) following bone marrow transplant. These patients received non-myeloablative conditioning followed by T-cell replete bone marrow from partially HLA-mismatched (haploidentical), related donors. Graft failure occurred in 9/66 (13%) of patients and was fatal in 1. Grade II-IV and III-IV acute GVHD cumulatively occurred in 34% and 6%, respectively, by day 200 after transplant. The cumulative incidence of non-relapse mortality and relapse at 1 year was 15% and 51%, respectively. OS and EFS at 2 years after transplantation were 36% and 26%, respectively. These results demonstrated that use of posttransplant high-dose CY induces selective allo depletion inhibiting severe GVHD and fatal graft rejection.
SIMULTANEOUS ALLOGENEIC HCT AND RENAL TRANSPLANT IN PATIENTS WITH NON-HEMATOLOGICAL DISORDERS AND DIALYSIS-DEPENDENT RENAL FAILURE
Kawai et al. 35 reported results of combined renal and HCT from HLA single-haplotype mismatched living related donors (parents or siblings) using a non-myeloablative conditioning regimen. The study was based on animal studies where allograft tolerance was induced by initial HCT grafts obtained from prospective solid organ donors. Using non-myeloablative conditioning created a donor and recipient lymphohematopoietic chimera allowing both the donor and recipient hematopoietic elements to coexist. 36, 37 The recipient animals then demonstrated tolerance to MHCmismatched renal allografts. [38] [39] [40] [41] The group presented their data on five HLA-mismatched donor-recipient combinations, four of whom maintained stable renal allograft function at a follow-up of 2-5.3 years after complete withdrawal of immunosuppressive drugs 35 (Table 4) . It is important to note that the donor-recipient chimerism achieved in the patients was of a transient nature and was not associated with the development of GVHD. Multilineage blood cell chimerism was detected by flow cytometry in all the five patients 7 days after transplant but not after day 21, even with PCR assays. Although the mechanism underlying the subsequent stable graft function in the absence of continued immunosuppression is not entirely clear, animal studies indicate that the transient chimerism is associated with depletion of thymic T cells that are reactive to donor Ag, also known as 'central depletion'. This postulate is (TABLE 5) The allogeneic effect is necessary to mediate graft-versus-tumor in the case of hematopoietic malignancies; a more prolonged, mixed chimerism state, however, may be desirable in the case of PCM in order to delay the onset of GVHD and a higher treatment-related mortality. Further, mixed chimerism also may prevent or delay rejection of the renal allograft. Fudaba et al. 43 reported six PCM patients treated with simultaneous non-myeloablative allogeneic BM transplant (using CY, antithymocyte globulin and thymic irradiation) and renal transplants. Additionally, they administered CYA for approximately 2 months after transplant followed by donor lymphocyte infusions. Although three patients lost detectable chimerism, they continued to maintain tolerance to the kidney graft in the absence of immunosuppression. Two patients achieved full donor chimerism but developed GVHD necessitating immunosuppressive therapy. Only one patient experienced renal allograft rejection after discontinuation of CYA. This subject, however, responded to resumption of immunosuppressive therapy and maintained stable renal function allowing discontinuation of antirejection medication after 1 year. Three of the six patients also achieved sustained CRs of myeloma at 42, 44 and 47 years. One patient who had progressive disease was retreated with chemotherapy followed by a myeloablative HCT from the same donor at 2.1 years. This patient had normal renal function at follow-up of 3.5 years from initial transplant. The same group recently presented longer follow-up data on these same patients with the addition of one more who underwent Renal allograft in myeloma L Nayak and HM Lazarus simultaneous HCT and renal transplantation. 44 All the seven patients demonstrated mixed chimerism, one patient developed acute GVHD and two had chronic GVHD. Five patients are alive, of which four have no evidence of PCM at 4-12.1 years post transplant. Although the underlying mechanism leading to renal allograft tolerance is attributed to mHA present primarily on the hematopoietic cells and not on the kidney, further research may be necessary to understand the underyling mechanisms involved in immune tolerance. Hence, this approach offers a potentially curative option using a less toxic conditioning regimen that is associated with renal allograft tolerance without the necessity for long-term immunosuppression.
ROLE OF BORTEZOMIB IN RENAL TRANSPLANTATION
Although the US Renal Data System database from 2009 reports the risk of renal allograft rejection of o12% in the first year after transplant, highly sensitized graft recipients are at a higher risk of Ab-mediated rejection. 45 Presently, there are no consensus guidelines for management of desensitization and Ab-mediated rejection. Most protocols include therapy with i.v. IG, plasmapheresis, rabbit antithymocyte globulin and rituximab. [46] [47] [48] Although current data suggest that plasma cells have an important role in graft rejection, there are concerns that presently used protocols do not target these cells. 49, 50 Bortezomib, a proteasome inhibitor used in the therapy of PCM, depletes plasma cells and has been utilized by several transplant groups for treatment of Abmediated rejection. 48 Bortezomib also exerts indirect effects on circulating B and T H cells. 51 The ability to target Ab-producing plasma cells has lead to its use in both desensitization and rejection protocols. Although some studies show promise, the presence of additional therapies (rituximab and i.v. IG) makes interpretation of the data and efficacy of bortezomib in the transplant desensitization and Ab-mediated rejection difficult. The outcome of more clinical trials addressing this issue is awaited.
CONCLUSIONS
HCT and renal transplant is a feasible option in patients with PCM and dialysis-dependent renal failure. The data suggest flexibility for allogeneic donor graft sources. In carefully selected patients with suitable donors, combined kidney and allogeneic HCT can treat both the plasma cell malignancy as well as the kidney failure. Nonmyeloablative and reduced-intensity pretreatment conditioning regimens may be associated with decreased toxicity typically associated with standard, myeloablative allogeneic HCT. This approach allows for the development of transient chimerism enabling renal allograft tolerance and avoidance of long-term immunosuppression with its associated complications. Although there is a concern for renal allograft rejection upon withdrawal of immunosuppression, data suggest that resumption of antirejection therapy leads to stable renal function. The role of bortezomib in preventing and treating Ab-mediated rejection appears promising. This agent possesses very effective anti-myeloma properties and potentially can be used as a maintenance treatment in patients who have not achieved a CR, as well as prevent renal allograft rejection. Although the accounts in the literature that describe the dual transplants have included patients with long-term follow-up (47 years in some patients), it is possible, however, that there may be publication bias with only favorable results being reported. More research is necessary to further delineate the subset of PCM patients most likely to benefit from renal transplant. A special registry for data collection for long-term follow-up may be useful to improve upon future patient survival.
